Research programme: protein aggregation inhibitors - Proclara Biosciences

Drug Profile

Research programme: protein aggregation inhibitors - Proclara Biosciences

Alternative Names: NPT-001; NPT-002 - Proclara Biosciences

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator NeuroPhage Pharmaceuticals
  • Developer Proclara Biosciences
  • Class Bacteriophages
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 07 Sep 2016 NeuroPhage Pharmaceuticals is now called Proclara Biosciences
  • 26 Jun 2013 Antitope has been acquired by PolyTherics
  • 13 May 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top